Mcdaniel Terry & Co. Sells 120 Shares of Medtronic PLC $MDT

Mcdaniel Terry & Co. lowered its position in Medtronic PLC (NYSE:MDT) by 1.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 8,448 shares of the medical technology company’s stock after selling 120 shares during the period. Mcdaniel Terry & Co.’s holdings in Medtronic were worth $736,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. 1248 Management LLC purchased a new stake in shares of Medtronic in the first quarter worth approximately $26,000. Columbia River Financial Group LLC bought a new position in Medtronic in the 1st quarter valued at $28,000. Twin Tree Management LP purchased a new stake in Medtronic in the first quarter worth $29,000. Activest Wealth Management lifted its position in shares of Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares during the last quarter. Finally, Hughes Financial Services LLC purchased a new stake in shares of Medtronic during the first quarter valued at $32,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MDT. BTIG Research reiterated a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Saturday. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. Robert W. Baird upped their price target on shares of Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. Finally, Evercore ISI lifted their price objective on shares of Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average price target of $102.82.

Insider Transactions at Medtronic

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the stock in a transaction on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.26% of the company’s stock.

Medtronic Trading Down 0.5%

NYSE:MDT opened at $93.76 on Friday. The stock has a market capitalization of $120.26 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 2.48 and a beta of 0.78. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm has a 50 day moving average of $94.32 and a 200 day moving average of $89.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s dividend payout ratio is currently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.